News

In a recent meeting members of both boards analyzed preliminary Phase IIa safety and efficacy data from CardioCell’s on-going chronic heart failure (HF) study, "Single-blind, Placebo-controlled, Crossover, Multi-center,

About 12,000 patients were enrolled at over 470 sites in eight countries. The five-year study will evaluate the impact of long-term treatment with Belviq CIV on the occurrence

Retinoblastoma generally affects children before the age of three. It is rarely found in adults. Cellceutix said the eye cancer is sight threatening and potentially fatal if not

Crispr-Cas9 is a DNA cutting and pasting system and by tweaking the system the scientists claim they can safely and accurately edit human genes for curing inherited or

Under terms of the Agreement, Axella will contribute over $1m in funding and the delivery of key clinical research organization (CRO) services, including the management and execution of

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. The open label Phase IIa study (the

The milestone stems from Sanofi’s decision to continue advancing the tetraspecific Anticalin-based program for infectious disease. The drug candidate selectively binds four classes of siderophores produced by Pseudomonas

The strategic move between Takeda, an R&D driven pharmaceutical company which has a long history as a leading company in Japan, and Teva, among the top ten pharmaceutical

The approval of this first and only immunostimulatory antibody for multiple myeloma is based on data from the randomized, open-label, Phase 3, ELOQUENT-2 study, which demonstrated that the